Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of lenvatinib (E7080) in advanced thyroid cancer
jRCT2080221963Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in thyroid cancer, well-differentiated thyroid cancer (WDTC) and Medullary Thyroid Cancer (MTC), sponsored by Eisai Co., Ltd. Started Nov 2012; status: completed.
02
Drugs
lenvatinib
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on jRCT2080221963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221963.